Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

128
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
128
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase I design for partially ordered groups with late-onset toxicity.

Clinical trials (London, England)·2026
Same author

Geographic Analysis of Access to the National Diabetes Prevention Program in New York State.

Preventive medicine reports·2026
Same author

Residual-Based Sieve Maximum Full Likelihood Estimation for the Proportional Hazards Model.

Communications in statistics: theory and methods·2026
Same author

Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.

JCO precision oncology·2026
Same author

Pertuzumab and Trastuzumab in Patients With <i>ERBB2/3</i>-Altered Urothelial or Ovary/Fallopian Tube Cancer: Results From the Targeted Agent and Profiling Utilization Registry Study.

JCO precision oncology·2026
Same author

Temsirolimus in Patients With Solid Tumors With <i>PIK3CA</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

JCO precision oncology·2026
Same journal

Public Health Response to Clade Ib Mpox with Multiple Exposures in Congregate Living Settings - New Hampshire, February 2025.

NEJM evidence·2026
Same journal

Berberine-Ursodeoxycholate - Bringing Traditional Chinese Medicine to Our World.

NEJM evidence·2026
Same journal

Outbreak of Legionnaires' Disease Associated with Cooling Tower Systems in Central Harlem.

NEJM evidence·2026
Same journal

Immunotherapy for Fertility in Autoimmune Premature Ovarian Insufficiency.

NEJM evidence·2026
Same journal

A Randomized Trial of Interval Likelihood Ratios for Clinical Decision-Making.

NEJM evidence·2026
Same journal

Evidence for Evidence-Based Medicine - A Call for Some Theory and a New Problem.

NEJM evidence·2026
See all related articles

Related Experiment Video

Updated: Jul 4, 2025

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
00:04

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.7K

Randomized Phase I Trials - One Size Fits All?

Susan Halabi1, Codruta Chiuzan2

  • 1Department of Biostatistics and Bioinformatics, Duke University, Durham, NC.

NEJM Evidence
|February 6, 2024
PubMed
Summary
This summary is machine-generated.

ARO-APOC3, a novel RNA therapeutic, demonstrated a favorable safety profile and effectively reduced apolipoprotein C-III (APOC3) levels in a Phase I trial for hypertriglyceridemia. This offers a promising new avenue for managing high triglyceride levels.

More Related Videos

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.7K
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

2.8K

Related Experiment Videos

Last Updated: Jul 4, 2025

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
00:04

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.7K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.7K
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

2.8K

Area of Science:

  • Pharmacology
  • Genetics
  • Clinical Trials

Background:

  • Apolipoprotein C-III (APOC3) plays a key role in triglyceride metabolism and is a therapeutic target for hypertriglyceridemia.
  • Small interfering RNA (siRNA) therapeutics offer a targeted approach to reduce the expression of specific genes, such as APOC3.
  • Phase I trials are crucial for evaluating the safety, tolerability, and preliminary pharmacodynamics of new drug candidates.

Discussion:

  • The Phase I trial of ARO-APOC3, a siRNA targeting APOC3 mRNA, assessed its safety and pharmacodynamics in healthy volunteers and patients with hypertriglyceridemia.
  • Participants received escalating doses of ARO-APOC3 or placebo in single- and/or repeat-dose regimens.
  • An open-label cohort evaluated ARO-APOC3 in patients with chylomicronemia, a severe form of hypertriglyceridemia.

Key Insights:

  • ARO-APOC3 demonstrated a generally favorable safety profile across the studied dose range.
  • Pharmacodynamic assessments indicated that ARO-APOC3 effectively reduced APOC3 mRNA expression, suggesting target engagement.
  • The study provides initial evidence for the potential therapeutic benefit of ARO-APOC3 in conditions characterized by elevated triglycerides.

Outlook:

  • Further clinical trials are warranted to confirm the efficacy and long-term safety of ARO-APOC3 in larger patient populations.
  • ARO-APOC3 represents a potential new therapeutic strategy for managing hypertriglyceridemia and related cardiovascular risks.
  • The development of siRNA-based therapies like ARO-APOC3 holds promise for precision medicine in cardiovascular disease.